General form of registration statement for all companies including face-amount certificate companies

Consolidated Statements of Cash Flows

v3.24.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Operating activities:        
Net loss $ (13,483) $ (1,848) $ 18,691 $ (27,552)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation 562 454 603 427
Changes in operating assets and liabilities:        
Prepaid expenses and other assets (243) 290 273 695
Accrued expenses and other liabilities 1,408 (1,040) (1,177) (1,054)
Net cash used in operating activities (5,447) (11,276) (13,703) (14,840)
Financing activities:        
Proceeds from exercise of stock options     0 34
Net cash provided by financing activities 12,304 0 5,000 9,566
Net increase in cash and cash equivalents 6,857 (11,276) (8,703) (5,274)
Cash and cash equivalents at beginning of period 7,350 16,053 16,053 21,327
Cash and cash equivalents at end of period 14,207 4,777 7,350 16,053
Pieris Pharmaceuticals, Inc. [Member]        
Operating activities:        
Net loss (11,369) (19,959) (24,543) (33,277)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization (accretion)     1,904 2,770
Right-of-use asset accretion 0 (98) (123) 10
Stock-based compensation 1,223 2,898 3,349 4,402
Asset impairment 0 14,893 13,912 0
Realized investment losses 0 (53) (53) (376)
Other non-cash transactions 864 (129) (124) (91)
Changes in operating assets and liabilities:        
Accounts receivable     5,307 (2,624)
Prepaid expenses and other assets     1,018 (1,358)
Deferred revenue     (39,967) (20,185)
Account payable     (789) (4,208)
Accrued expenses and other liabilities     (2,336) (4,005)
Lease liability, prior to operating lease termination     (868) (990)
Change in lease liability due to termination of operating lease     (10,506) 0
Net cash used in operating activities (8,330) (34,150) (53,819) (59,932)
Investing activities:        
Purchases of property and equipment 0 (184) (171) (1,041)
Proceeds from maturity of investments 9,000 24,007 35,008 28,200
Purchases of investments 0 (15,270) (22,835) (48,395)
Net cash provided by investing activities 11,318 8,553 12,002 (21,236)
Financing activities:        
Proceeds from exercise of stock options     0 95
Proceeds from employee stock purchase plan 0 52 66 197
Proceeds from issuance of common stock resulting from ATM sales, net of $0.7 million in transaction costs 0 19,729 19,729 6,922
Net cash provided by financing activities 0 19,781 19,795 7,214
Effect of exchange rate change on cash and cash equivalents (1,021) 75 783 (5,175)
Net increase in cash and cash equivalents 1,967 (5,741) (21,239) (79,129)
Cash and cash equivalents at beginning of period 17,396 38,635 38,635 117,764
Cash and cash equivalents at end of period 19,363 32,894 17,396 38,635
Supplemental cash flow disclosures:        
Net unrealized gain (loss) on investments $ (1) $ 74 74 (73)
Property and equipment included in accounts payable     $ 0 $ 193